Provided by Tiger Trade Technology Pte. Ltd.

Praxis Precision Medicines, Inc.

330.55
-4.0300-1.20%
Pre-market: 329.00-1.5500-0.47%04:13 EDT
Volume:375.63K
Turnover:124.74M
Market Cap:9.21B
PE:-25.70
High:341.71
Open:337.67
Low:328.95
Close:334.58
52wk High:392.70
52wk Low:40.12
Shares:27.85M
Float Shares:24.08M
Volume Ratio:1.56
T/O Rate:1.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.8634
EPS(LYR):-13.4758
ROE:-38.86%
ROA:-25.65%
PB:6.86
PE(LYR):-24.53

Loading ...

Praxis Precision Medicines (PRAX) Gets a Buy from Truist Financial

TIPRANKS
·
Jun 02

Piper Sandler Remains a Buy on Praxis Precision Medicines (PRAX)

TIPRANKS
·
Jun 02

Deutsche Bank Adjusts Praxis Precision Medicines PT to $374 From $420, Maintains Buy Rating

MT Newswires Live
·
Jun 02

Guggenheim Sticks to Its Buy Rating for Praxis Precision Medicines (PRAX)

TIPRANKS
·
Jun 02

S&P 500 Futures Fall In Premarket Trading; Hewlett Packard Ent, Marvell Technology Lead

Dow Jones
·
Jun 02

Wells Fargo Sticks to Its Hold Rating for Praxis Precision Medicines (PRAX)

TIPRANKS
·
Jun 02

Buy Rating Reaffirmed as Higher Relutrigine Pricing Assumptions Offset Vormatrigine Setback; $537 Price Target Maintained

TIPRANKS
·
Jun 02

Yazdi Maintains Buy on Praxis, Trims Price Target to $810 as Vormatrigine Outlook Softens but Core Pipeline Thesis Remains Intact

TIPRANKS
·
Jun 02

Praxis Precision Medicines Inc : TD Cowen Cuts Target Price to $510 From $554

THOMSON REUTERS
·
Jun 02

Praxis Precision price target lowered to $1,201 from $1,245 at H.C. Wainwright

TIPRANKS
·
Jun 02

Praxis Precision Medicines, Inc. : H.c. Wainwright Cuts Target Price to $1201 From $1245

THOMSON REUTERS
·
Jun 02

Praxis Precision Med Is Maintained at Buy by BTIG

Dow Jones
·
Jun 02

U.S. RESEARCH ROUNDUP-Edgewise Therapeutics, IBM, Rubrik

Reuters
·
Jun 02

Praxis Precision Medicines Inc : Baird Cuts Target Price to $400 From $433

THOMSON REUTERS
·
Jun 02

Praxis Precision Reassesses Vormatrigine After Mixed POWER1 Data

TIPRANKS
·
Jun 02

Praxis Precision Medicines's Seizure Treatment Fails to Meet Trial's Primary Endpoint

Dow Jones
·
Jun 02

Praxis Precision reports POWER1 study misses endpoint, pauses POWER2 enrollment

TIPRANKS
·
Jun 02

Praxis says POWER1 trial of vormatrigine in focal seizures misses primary endpoint

Reuters
·
Jun 02

Praxis Precision Medicines - Power1 Study Did Not Meet Primary Endpoint in Refractory Focal Onset Seizures

THOMSON REUTERS
·
Jun 02

Praxis Precision Medicines - Pauses Enrollment in Power2 Study to Reassess Vormatrigine Program

THOMSON REUTERS
·
Jun 02